Menu
Fechar
HRS4R
Vull donar

ARIADNA GIFREU FRAIXINÓ

Neurodegeneració i Neuroinflamació
Firma
ARIADNA GIFREU-FRAIXINÓ
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1
Projectes
Publicacions

Projectes

Neurodegeneració i Neuroinflamació

PROCOGBIO Predicción de la progresión del deterioro cognitivo en la esclerosis múltiple combinando biomarcadores circulantes en sangre

Codi oficial: PI23/00517 Data inici: 01/01/2024 Data fi: 31/12/2026 Investigador/a principal: ANNA QUIROGA VARELA, LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Bravo, GCA, Quiroga-Varela, A, Gifreu, A, Pons, JMH, Lago, AB, Benavides, AM, Ramió-Torrentà, L

Echopraxia, an underrecognized clinical sign in multiple sclerosis: a biological and neuroimaging framework

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 743-743
Bravo, GCA, Gifreu, A, Quiroga-Varela, A, Lago, AB, Pons, JMH, Benavides, AM, Torrenta, LRI

First case of rebound effect after Ozanimod discontinuation

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1081-1082
Pons, JMH, Coll-Martínez, C, Benavides, AM, Gifreu, A, Pont, JS, Bravo, GCA, Fulla, JG, Torrenta, LRI, Quiroga-Varela, A

Interleukin-8 plasma levels as a potential biomarker for predicting middle-term cognitive outcomes

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 976-977
Coll-Martínez, C, Pont, JS, Pons, JMH, Benavides, AM, Gifreu, A, Bravo, GCA, Quiroga-Varela, A, Ramió-Torrentà, L, Fulla, JG

Cognitive outcomes through MS disease course: 10-year follow-up

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 747-748
Coll-Martínez, C, Pons, JMH, Benavides, AM, Bravo, GCA, Gifreu, A, Pont, JS, Fulla, JG, Torrenta, LRI, Quiroga-Varela, A

Prognostic potential of plasma Interleukin-6 levels as biomarker for long-term cognitive performance

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 981-981
Guirao, M, Valverde, S, Bramon, R, Clèrigues, A, Tovar, A, Cámara-Vázquez, MA, Valencia, L, Nersesyan, N, Bravo, GCA, Casadevall, MP, Gifreu, A, Oliver, A, Llado, X, Cañellas, AR, Ramió-Torrentá, L

Improving generalization of MRI-based detection of new T2 lesions through fine-tuning deep learning methods

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 288-289
Benavides, AM, Pons, JMH, Coll-Martínez, C, Gifreu, A, Bravo, GCA, Torrenta, LRI, Quiroga-Varela, A

Circulating miR-197-3p and miR-1-3p in plasma as potential biomarkers of mitochondrial dysfunction in Primary Progressive Multiple Sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 589-590
Gifreu-Fraixinó, A, Boix-Lago, A, Alvarez-Bravo, G, Quiroga-Varela, A, Miguela-Benavides, A, Huertas-Pons, JM, Coll-Martínez, C, Ramió-Torrentà, L

Effectiveness of high-efficacy disease-modifying therapies in naive patients with relapsing-remmiting multiple sclerosis compared with the escalation regimen

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1089-1089
Quiroga-Varela, A, Pons, JMH, Coll-Martínez, C, Benavides, AM, Pont, JS, Gifreu, A, Bravo, GCA, Fulla, JG, Ramió-Torrentà, L

Exploring neurogranin as a potential biomarker for cognitive impairment and disease activity in multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 590-590
Gifreu-Fraixinó, A, Boix-Lago, A, Alvarez-Bravo, G, Miguela-Benavides, A, Huertas-Pons, JM, Quiroga-Varela, A, Coll-Martínez, C, Ramió-Torrentà, L

Defining the profiles of patients who receive high-efficacy disease-modifying therapies for multiple sclerosis in real clinical practice

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1094-1095

Formulari de contacte

Coneix l’IDIBGI!

 menu